Payment overview · 2025
General Payments
$258,771.09
499 reported records · 25 companies
Healthcare provider profile · identity verified
James E. Mossell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TIFTON, GA · NPI 1720195837
Verified facts
What the public records show
CMS Open Payments records show James E. Mossell, D.O. received $258,771.09 in general payments during 2025 across 499 reported records.
Amgen Inc. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Acthar, Benlysta, Kevzara, Krystexxa, Orencia, Otezla, Panzyga, Rinvoq, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Krystexxa by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Orencia by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Kevzara by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Actemra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Simponi by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Acthar by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Panzyga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Panzyga by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $81,604.44 | 31.5% | 134 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57,306.00 | 22.1% | 88 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $36,259.36 | 14.0% | 60 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26,115.25 | 10.1% | 29 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21,031.46 | 8.1% | 42 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $14,100.40 | 5.5% | 20 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $9,700.53 | 3.8% | 20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5,897.37 | 2.3% | 16 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $2,639.67 | 1.0% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $2,527.39 | 1.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $424.89 | 0.2% | 22 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $174.56 | 0.1% | 8 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $164.45 | 0.1% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $141.36 | 0.1% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.72 | 0.1% | 7 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $135.43 | 0.1% | 11 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $75.95 | 0.0% | 3 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.31 | 0.0% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $53.54 | 0.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $49.34 | 0.0% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $43.46 | 0.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $40.91 | 0.0% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $32.27 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $26.74 | 0.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.29 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $162,487.50 | 82 |
| Travel and Lodging | $51,502.87 | 119 |
| Consulting Fee | $19,287.08 | 10 |
| Honoraria | $15,600.00 | 10 |
| Food and Beverage | $9,703.65 | 276 |
| Education | $189.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38,955.10 | 65 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $36,259.36 | 60 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32,943.31 | 42 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $29,845.72 | 38 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $26,155.97 | 55 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $26,115.25 | 29 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $21,031.46 | 42 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $14,100.40 | 20 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $9,700.53 | 20 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $9,230.32 | 19 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $2,568.30 | 11 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | Octapharma USA, Inc., PFIZER INC. | $264.84 | 12 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $226.33 | 13 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $174.56 | 8 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $164.45 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $156.09 | 7 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $141.36 | 7 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $136.72 | 7 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $135.43 | 11 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $134.70 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $113.39 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $108.20 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $75.95 | 3 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $70.31 | 3 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $49.34 | 2 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $43.46 | 2 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $28.90 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ACTHAR acthar |
2025 | Acthar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 106 | exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 122 | exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 55 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
122 | 22 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
106 | 12 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 975 | 216 |
| Gabapentin | Gabapentin | 561 | 139 |
| Allopurinol | Allopurinol | 520 | 119 |
| Prednisone | Prednisone | 445 | 102 |
| Pregabalin | Pregabalin | 399 | 75 |
| Alendronate Sodium | Alendronate Sodium | 329 | 74 |
| Methotrexate | Methotrexate Sodium | 321 | 83 |
| Tramadol Hcl | Tramadol Hcl | 306 | 82 |
| Leflunomide | Leflunomide | 304 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 277 | 56 |
| Celecoxib | Celecoxib | 210 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 44 |
| Meloxicam | Meloxicam | 190 | 57 |
| Humira(Cf) Pen | Adalimumab | 171 | 26 |
| Colchicine | Colchicine | 165 | 39 |
| Baclofen | Baclofen | 153 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 124 | 50 |
| Enbrel Mini | Etanercept | 123 | 17 |
| Orencia Clickject | Abatacept | 123 | 25 |
| Kevzara | Sarilumab | 122 | 22 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 117 | 31 |
| Famotidine | Famotidine | 111 | 31 |
| Benlysta | Belimumab | 106 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 16 |
| Sulfasalazine | Sulfasalazine | 84 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 27 |
| Sulindac | Sulindac | 80 | 22 |
| Azathioprine | Azathioprine | 79 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 11 |
| Methocarbamol | Methocarbamol | 68 | 29 |
| Nabumetone | Nabumetone | 68 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 14 |
| Minocycline Hcl | Minocycline Hcl | 63 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Methylprednisolone | Methylprednisolone | 60 | 23 |
| Furosemide | Furosemide | 57 | 14 |
| Rinvoq | Upadacitinib | 55 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 53 | 19 |
| Orencia | Abatacept | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 13 |
| Folic Acid | Folic Acid | 51 | 16 |
| Potassium Chloride | Potassium Chloride | 49 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 15 |
| Etodolac | Etodolac | 42 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 41 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 14 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 36 | suppressed |
| Febuxostat | Febuxostat | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 28 |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Otezla | Apremilast | 31 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 29 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 28 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 27 | suppressed |
| Dapsone | Dapsone | 26 | suppressed |
| Probenecid | Probenecid | 24 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Savella | Milnacipran Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 21 | suppressed |
| Actemra | Tocilizumab | 20 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 19 | suppressed |
| Enbrel Sureclick | Etanercept | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Acthar | Corticotropin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Krystexxa | Pegloticase | 16 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 15 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Nystatin | Nystatin | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Trexall | Methotrexate Sodium | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Flurbiprofen | Flurbiprofen | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 12 | suppressed |
| Simponi | Golimumab | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 11 | 11 |
| Bumetanide | Bumetanide | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258,771.09 · 499 records | Amgen Inc. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, CUTAQUIG, CUVITRU, EUFLEXXA, EVENITY, Gazyva, Hizentra, KEVZARA, KRYSTEXXA, Kineret, LUPKYNIS, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, ORENCIA, OTEZLA, PANZYGA, PURIFIED CORTROPHIN GEL, RINVOQ, SAPHNELO, SKYRIZI, TAVNEOS, TREMFYA, Tyenne, Tymlos, UPLIZNA, XELJANZ, Xembify, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error